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acterized	 by	 adipose	 tissue	 loss.	 Proteinuria	 is	 a	 remarkable	 finding	 in	 previous	
reports.
Study design:	 In	 this	multicentre	 study,	prospective	 follow-	up	data	were	collected	
from	103	subjects	with	non-	HIV-	associated	lipodystrophy	registered	in	the	Turkish	
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1  | INTRODUC TION
Lipodystrophy	 syndromes	 are	 a	 group	of	 heterogeneous	disorders	
affecting	adipose	tissue	differentiation	or	distribution	as	well	as	me-
tabolism.	Congenital	generalized	lipodystrophy	(CGL)	is	a	rare,	mostly	
autosomal	 recessive	 disorder	 characterized	 by	 near	 total	 absence	
of	 the	body	adipose	 tissue.	Several	genes	have	been	 identified	 for	
CGL	which	includes	1-	acylglycerol-	3-	phosphate	O-	acyltransferase	2	
(AGPAT2),	Berardinelli-	Seip	congenital	lipodystrophy	2	(BSCL2),	cave-





of	FPLD,	FPLD2	 is	caused	by	heterozygous	mutations	 in	 the	 lamin	
A/C	 (LMNA)	 gene.2	 In	 acquired	 lipodystrophy	 syndromes,	 patients	
develop	adipose	tissue	loss	at	some	point	during	life.3





















2  | MATERIAL S AND METHODS
2.1 | Patients
Initially,	 109	 patients	 non-	HIV	 associated	 lipodystrophy	 from	
the	TuLip	registry	were	included	in	this	study.	None	of	the	pa-
tients	 received	metreleptin	 or	 any	 other	 drug	 in	 development	
for	 lipodystrophy	 at	 the	 time	of	 data	 collection.	 Patients	with	



















ent	 underlying	 genetic	 defects	 may	 also	 lead	 to	 cell	 autonomous	 mechanisms	
contributory	to	the	pathogenesis	of	kidney	disease.
K E Y W O R D S
chronic	kidney	disease,	insulin	resistance,	lipodystrophy,	proteinuria
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syndrome	 and	Candle/JMP	 syndrome	were	 excluded	 from	 the	
study.	 Five	 patients	were	 not	 included	 in	 the	 analysis	 as	 they	
either	did	not	have	a	 regular	 follow-	up	 for	 renal	complications	
or	refused	to	attend	the	data	collection	visits.	Another	patient	
with	 partial	 lipodystrophy	 was	 excluded	 as	 he	 was	 diagnosed	
with	 systemic	 lupus	 erythematosus,	 and	 lupus	 nephritis	 was	
detected	 on	 the	 renal	 biopsy.	 The	 study	was	 approved	 by	 the	
Dokuz	Eylul	University	Ethics	Review	Panel.	Written	 informed	
consent	was	obtained.
2.2 | Diagnosis and classification of lipodystrophy
CGL	 was	 diagnosed	 based	 on	 generalized	 adipose	 tissue	 loss	
that	was	 remarkable	 at	 birth	 or	 noticed	 at	 early	 stages	 of	 life.	
Acquired	generalized	lipodystrophy	(AGL)	was	diagnosed	based	
on	 the	 development	 of	 generalized	 adipose	 tissue	 loss	 later	
on	 in	 childhood	 or	 later.	 FPLD	was	 diagnosed	 based	 on	 partial	
adipose	tissue	 loss	 in	selected	areas.	APL	was	diagnosed	based	
on	 acquired	 adipose	 tissue	 loss	 characteristically	 starting	 at	
the	 face,	 progressing	 in	 a	 cephalocaudal	 fashion	 to	 the	 trunk	
and	upper	extremities.	Adipose	 tissue	distribution	was	also	as-
sessed	 by	 whole-	body	 magnetic	 resonance	 imaging	 (WB	 MRI;	
Gyroscan	Intera,	release	8.1;	Philips	Medical	Systems,	Best,	the	
Netherlands)	 with	 a	 6-	multichannel	 body	 coil.	Mutation	 analy-
sis	 of	 the	 genes	 LMNA, LMNB2, PPARG, AGPAT2, BSCL2, CAV1, 
PTRF, PLIN1, AKT2, LIPE, ADRA2A, ZMPSTE24 and CIDEC	 was	
carried	out	by	direct	 automated	DNA	sequencing	 from	 the	pa-
tients’	genomic	DNA,	based	on	the	clinical	features.	Sequencing	
was	 performed	with	Miseq	V2	 chemistry	 on	MiSeq	 instrument	
(Illumina,	California,	USA).
2.3 | Data collection and analysis
The	prospective	follow-	up	data	were	collected	by	the	investigators	




on	 antihypertensive	 treatment	 and	 those	with	 resting	 blood	 pres-
sure	 higher	 than	140/90	mm	Hg	were	 considered	 as	 hypertensive.	
For	the	paediatric	age	group,	adjusted	blood	pressure	for	age,	height	
and	 gender	 higher	 than	 95th	 percentile	was	 considered	 as	 having	
hypertension.
Patients	underwent	a	detailed	physical	examination,	 full	bio-
chemistry	 and	 urinalysis	 for	 protein	 content.	 Biochemical	 tests	
were	 studied	 by	 standardized	methods	with	 appropriate	 quality	
control	 and	quality	 assurance	procedures.	Direct	 low-	density	 li-
poprotein	(LDL)	cholesterol	measurement	was	performed.	Leptin	
and	 adiponectin	 levels	 were	 measured	 with	 enzyme-	linked	 im-
munosorbent	 assay	 (ELISA)	 according	 to	 the	 manufacturer’s	
instructions	 (Boster,	 Pleasanton,	 CA,	 USA).	 Diabetes	 was	 de-
fined	 according	 to	 the	 recommendations	 of	 American	 Diabetes	
Association	 (ADA).9	 Lipid	 levels	were	classified	according	 to	 the	
National	 Cholesterol	 Education	 Program	Adult	 Treatment	 Panel	
(NCEP	ATP	III)	guidelines.10	Age-	specific	thresholds	were	used	for	
children	and	adolescents.11
We	 defined	 chronic	 kidney	 disease	 (CKD)	 as	 abnormalities	
of	 kidney	 structure	 or	 function,	 which	 persisted	 for	 at	 least	
3	months.	Estimated	GFR	(eGFR)	was	calculated	using	the	CKD-	
EPI	formula.12	Bedside	Schwartz	formula	was	used	for	children.13 
eGFR	 and	 proteinuria	 were	 classified	 according	 to	 the	 Kidney	
Disease	Outcomes	Quality	Initiative	(KDOQI)	and	updated	guide-
line	of	the	Kidney	Disease	Improving	Global	Outcomes	(KDIGO).14 




Positive	 dipstick	 test	 results	 were	 followed	 by	 a	 quantitative	
measurement.	 In	adults	 (≥18	years),	urinary	protein	excretion	of	
≥	 150	mg/d	 was	 considered	 to	 be	 abnormal.	 Microalbuminuria	
(moderately	 increased	 albuminuria)	 was	 diagnosed	 from	 a	 24-	
hours	urine	collection	(between	30	and	300	mg/d)	or	from	a	spot	
sample	 (30-	300	mg/g).	 Macroalbuminuria	 (severely	 increased	
albuminuria)	was	defined	as	an	albumin	excretion	≥300 mg/d	or	
≥300	 mg/g	on	a	spot	specimen.	Nephrotic	range	proteinuria	was	
considered	 with	 a	 protein	 excretion	 of	 3.5	g	 or	 more	 per	 day.	
Proteinuria	 in	 children	 was	 defined	 as	 greater	 than	 100	mg/m2 
urinary	protein	excreted	per	day.	On	a	spot	urine	protein/creati-
nine	test,	proteinuria	was	defined	as	a	ratio	>0.2	in	children	older	






renal	 disease	 (ESRD)	 was	 defined	 as	 having	 an	 eGFR	 less	 than	
15 mL/min/1.73 m2.	Elevated	eGFR,	which	may	 reflect	hyperfil-
tration,	was	considered	if	eGFR	exceeded	130	mL/min/1.73	m2 in 
adults	and	150	mL/min/1.73	m2	in	children.
2.4 | Measurement of kidney volumes
Kidney	morphology	was	studied	on	either	ultrasound	or	MRI.	Kidney	
volumes	were	measured	on	axial	3D	GRE	fat	saturated	T1	weighted	
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using	antibodies	against	IgG,	IgA,	IgM,	complement-	3	(C3),	comple-




Statistical	 analysis	 was	 performed	 using	 Statistical	 Package	
of	 Social	 Science	 (SPSS	 Inc,	 Chicago,	 IL,	 USA),	 version	 22	 for	




the	 relationship	 existing	 between	 continuous	 parameters.	 Partial	
correlations	 method	 was	 also	 used	 to	 measure	 the	 association	
between	 two	 variables	 while	 controlling	 the	 effect	 of	 additional	







(n = 44) P value
Age	(y) 21 ± 17 38 ± 15 <.001
Gender	(F/M) 21/16 35/9 .032
BMI	(kg/m2) 19.05 ± 3.25 23.73	±	4.87 .003
Follow-	up	(mo) 72 ± 56 57	±	84 .001
Diabetes/IGT 20	(54%)/3	(8%) 31	(71%)/4	(9%) .221
Duration	of	diabetes	(mo) 151 ± 97 127 ± 102 .403
Hypertension 8	(22%) 17	(39%) .147
Glucose	(mmol/L) 8.01	±	4.39 8.18	±	3.41 .851
HbA1c	(%) 7.63 ± 2.66 7.38	±	1.94 .629
HOMA-	IR	score 19.78 ± 25.21 9.88 ± 9.32 .025
ALT	(IU/L) 56 ± 55 31	±	24 .048
GGT	(IU/L) 69 ± 72 53 ± 59 .288
Total	cholesterol	(mmol/L) 5	±	2.43 5.66 ± 1.98 .023
LDL	cholesterol	(mmol/L) 2.34	±	1.13 2.94	±	1.14 .084
HDL	cholesterol	(mmol/L) 0.69 ± 0.26 0.89 ± 0.28 .069
Triglyceride	(mmol/L) 7.78	±	9.42 5.86	±	5.54 .258
Leptin	(ng/mL) 0.69 ± 0.81 6.47	±	6.54 <.001
Adiponectin	(μg/mL) 5.33 ± 7.98 9.01 ± 7.73 .033
Creatinine	(mg/dL) 1.1 ± 1.5 0.67 ± 0.21 .067
C3	(mg/dL) 137 ± 28 142	±	24 .469
CKD 17	(46%) 23	(52%) .657
eGFR	(mL/min/1.73	m2) 101	±	48 109 ± 23 .302







Nephrotic	range	proteinuria 5	(14%) 2	(5%) .237
eGFR<60	mL/min/1.73	m2 8	(22%) 3	(7%) .1
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3  | RESULTS
The	 GL	 and	 PL	 cohorts	 were	 previously	 reported	 to	 describe	


















podystrophy	had	significantly	 lower	 levels	of	 leptin	and	adiponec-
tin	(Table	1).	Proteinuria	was	almost	two	times	more	common	than	
retinopathy	 in	 patients	with	 generalized	 lipodystrophy	 (Table	 S1).	
Proteinuria	was	at	nephrotic	range	in	5	patients	(14%).	Also,	10	ad-
ditional	 patients	 (27%)	with	 generalized	 lipodystrophy	 had	 hyper-
filtration.	Eight	patients	 (22%)	with	generalized	 lipodystrophy	had	





Twenty-	nine	 patients	 (44%)	 with	 partial	 lipodystrophy	 devel-
oped	 CKD	 associated	 with	 proteinuria	 (Table	 S2).	 Three	 patients	
(5%)	had	proteinuria	at	nephrotic	range.	Five	patients	(8%)	had	hy-




















eralized	 lipodystrophy	 compared	 to	 those	with	 partial	 lipodystro-
phy	 (312	±	116	cm3	 vs	 223	±	48	cm3,	 P	=	.012	 for	 the	 left	 kidney;	
285	±	94	cm3	vs	216	±	49	cm3,	P	=	.016	for	the	right	kidney).	Kidney	
volumes	were	found	to	be	positively	correlated	with	fasting	glucose	
(r =	.602,	P	<	.001	 for	 the	 left	 kidney,	 Figure	1A;	 r	=	.499,	P = .002 








F IGURE  1 The	association	of	kidney	volume	with	metabolic	parameters	(1A,	B:	Glucose,	1C,D:	HOMA-	IR	score,	1E,F:	HbA1c,	1G,	 
H:	Leptin)
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Table	2	 summarizes	 the	 results	 of	 percutaneous	 renal	 biopsies	
and	the	clinical	features	of	patients	at	the	time	of	the	biopsy.	Renal	
biopsy	was	performed	 in	4	patients	with	generalized	 lipodystrophy	
(3	 patients	 with	 CGL	 caused	 by	 AGPAT2	 mutations	 and	 1	 patient	
with	AGL).	Glomerular	basal	membranes	 (GBMs)	were	 thickened	 in	







(Figure	2E)	 marked	 mesangial	 expansion	 with	 Kimmelstiel-	Wilson	
nodules	in	a	patient	with	FPLD	caused	by	an	LMNA	pathogenic	variant	










mesangial	 expansion	 and	 hypercellularity,	 thickening	 of	 GBMs	 and	
podocyte	injury.	Lipid	vacuoles	were	visualized	on	EM	images.
4  | DISCUSSION












complications.	 In	 addition,	 the	 different	 lifestyle	 conditions	 and	
dietary	 factors	may	be	modifying	disease	 course	 and	 the	 severity	
of	proteinuria.	However,	we	should	note	that	all	patients	with	CGL	
older	 than	26	years	were	 found	to	have	CKD	at	some	 level	 in	our	
registry.
Renal	 complications	were	 also	 frequently	 detected	 in	 patients	
with	 partial	 lipodystrophy,	 although	 the	 age	 of	 onset	 was	 older	
than	 those	with	 generalized	 lipodystrophy.	 Renal	 involvement	 has	
previously	been	reported	 in	 few	patients	with	FPLD.	Owen	et	al20 
reported	 the	 first	 case	of	FPLD	who	developed	mesangiocapillary	
glomerulonephritis	 type	 II	without	 low	circulating	C3	 levels.	Later,	











histopathologic	 features	 of	 diabetic	 nephropathy	 in	 humans	 are	
GBM	 thickening,	 podocytopenia,	 mesangial	 expansion,	 glomer-
ular	 and	 arteriolar	 hyalinosis	 and	 Kimmelstiel-	Wilson	 nodules.22 
The	 loss	 of	 podocyte	 function,	 which	 contributes	 to	 the	 integ-
rity	of	 the	glomerular	 filtration	barrier,	 is	 a	 key	event	 in	 the	de-
velopment	of	diabetic	nephropathy.23	Hyperfiltration,	which	was	
detected	 in	several	patients	 in	our	study,	 is	an	early	abnormality	
leading	to	diabetic	nephropathy.24	However,	we	should	note	that	
formula-	derived	 estimations	 are	 not	 always	 accurate	 in	 reflect-
ing	 real	 renal	 function	 in	patients	with	hyperfiltration	or	normal	
kidney	 functions.19	 Ludtke	et	al8	 showed	classical	 findings	of	di-
abetic	nephropathy	such	as	diffuse	and	nodular	glomerulosclero-
sis	 (Kimmelstiel–Wilson	 lesions)	and	early	 ischaemic	tubulopathy	
in	a	postmortem	study.	Javor	et	al5	mentioned	an	autopsy	report	
which	 revealed	 diabetic	 nodular	 glomerulosclerosis	 in	 a	 patient	
with	CGL.	In	another	postmortem	study,	Hague	et	al25	described	
atherosclerotic	 vascular	 changes	 in	 kidneys.	Histopathologically,	
most	patients	 in	our	biopsy	 registry	showed	several	characteris-
tics	of	diabetic	nephropathy	 such	as	GBM	thickening,	mesangial	




additional	 mechanisms	 might	 play	 a	 role	 in	 the	 development	 of	
CKD	in	lipodystrophy.
Epidemiological	 studies	 have	 shown	 that	 obesity	 and	 meta-
bolic	syndrome	are	independent	predictors	of	CKD,	which	suggests	
that	 renal	 abnormalities	may	 develop	 long	 before	 the	 appearance	
of	 diabetes	 in	 patients	 with	 insulin	 resistance.26	 Recently,	 several	
researchers	 described	 obesity-	associated	 proteinuria	 which	 pro-
gresses	 to	 renal	 dysfunction	 that	 was	 associated	 with	 mesangial	




mechanisms	 that	 place	 hemodynamic	 stress	 on	 an	 initially	 normal	
nephron	 population.27	 FSGS	 was	 a	 remarkable	 finding	 in	 our	 bi-
opsy	 specimens.	 FSGS	 has	 previously	 been	 reported	 in	 patients	
with	 lipodystrophy.4,5,28	One	can	assume	that	 the	pathogenesis	of	
secondary	FSGS,	which	is	presumably	due	to	the	insulin	resistance,	
might	 be	 somewhat	 common	 in	 obesity	 and	 lipodystrophy.	 FSGS	
may	be	 secondarily	mediated	by	 structural–functional	 adaptations	







Limited	 storage	 capacity	 of	 adipose	 tissue	 in	 lipodystrophy	






















reduction	 in	 the	 creatinine	 clearance	 of	 5	 patients	with	 glomer-
ular	 hyperfiltration	 was	 also	 reported	 in	 the	 same	 study.	 Later,	
Chong	et	al34	reported	a	51%	reduction	in	24-	hour	urinary	protein	
excretion	of	 generalized	 lipodystrophy	patients	when	 they	were	
treated	with	metreleptin	for	one	year.	Very	recently,	a	report	from	
our	group	described	the	first	patient	treated	with	metreleptin	for	
generalized	 lipodystrophy	 in	 Turkey,	 which	 resulted	 in	 a	 signifi-
cant	improvement	in	glycaemic	control	and	lipid	profile,	and	also	
a	 significant	 reduction	 in	 urinary	 protein	 excretion.35	While	 it	 is	
reasonable	to	assume	that	metreleptin	treatment	may	have	a	pos-
itive	impact	on	the	progression	of	kidney	disease	in	patients	with	
lipodystrophy,	 the	data	presented	 for	approval	of	metreleptin	 in	
the	USA	 included	a	number	of	patients	 in	whom	the	kidney	dis-



























tually	 to	 renal	 failure.	 Patients	with	 generalized	 lipodystrophy	 are	
at	the	highest	risk	as	the	onset	of	renal	complications	can	be	early.	
Renal	involvement	appears	to	be	multifactorial	and	may	at	least	be	
driven	 by	 either	 poorly	 controlled	 diabetes	 and/or	 the	 underlying	
severe	insulin	resistance.	Also,	ectopic	lipid	accumulation	or	specific	
genetic	 mechanisms	 can	 potentially	 play	 a	 role;	 however,	 further	
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